|
Sorrento Therapeutics, Inc. (SRNE): Business Model Canvas [Jan-2025 Updated]
US | Healthcare | Biotechnology | NASDAQ
|
- ✓ Fully Editable: Tailor To Your Needs In Excel Or Sheets
- ✓ Professional Design: Trusted, Industry-Standard Templates
- ✓ Pre-Built For Quick And Efficient Use
- ✓ No Expertise Is Needed; Easy To Follow
Sorrento Therapeutics, Inc. (SRNE) Bundle
In the rapidly evolving landscape of biotechnology, Sorrento Therapeutics (SRNE) emerges as a pioneering force, strategically navigating the complex world of innovative medical solutions. With a razor-sharp focus on transformative cancer immunotherapies, cutting-edge COVID-19 treatments, and regenerative medicine technologies, this dynamic biotech company is redefining the boundaries of medical research and therapeutic development. By leveraging advanced scientific platforms, strategic partnerships, and a robust intellectual property portfolio, Sorrento Therapeutics is not just developing treatments, but crafting personalized molecular medicine strategies that hold the potential to revolutionize healthcare and offer hope to patients facing challenging medical conditions.
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Key Partnerships
Strategic Collaborations with Academic Research Institutions
As of 2024, Sorrento Therapeutics has established research partnerships with the following academic institutions:
| Institution | Research Focus | Collaboration Year |
|---|---|---|
| University of California, San Diego | Immuno-oncology research | 2022 |
| Johns Hopkins University | Cancer immunotherapy development | 2023 |
Partnership with NantKwest for Cancer Immunotherapy Development
Sorrento's strategic partnership with NantKwest involves:
- Joint development of NK cell-based cancer therapies
- Collaborative research budget of $15.7 million in 2023
- Shared intellectual property rights for developed technologies
Licensing Agreements with Pharmaceutical Technology Companies
Current licensing agreements as of 2024:
| Company | Technology Licensed | Agreement Value |
|---|---|---|
| Celgene Corporation | Antibody drug conjugate platform | $22.5 million |
| Pfizer Inc. | Immunotherapy screening technologies | $18.3 million |
Joint Ventures in Biopharmaceutical Research and Development
Sorrento's active joint ventures in 2024:
- Aragen Bioscience - Drug discovery collaboration
- Total joint venture investment: $37.2 million
- Focus areas: Oncology and immunotherapy research
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Key Activities
Developing Innovative Cancer Immunotherapies
As of 2024, Sorrento has 10 active cancer immunotherapy programs in various stages of development. Total R&D investment in cancer immunotherapies: $87.3 million in 2023.
| Cancer Therapy Program | Development Stage | Estimated Investment |
|---|---|---|
| SRNE-C3 | Phase II Clinical Trials | $24.5 million |
| CAR-T Therapies | Preclinical Research | $18.7 million |
Conducting Clinical Trials for Proprietary Drug Candidates
Current clinical trial portfolio: 7 active trials across multiple therapeutic areas.
- Total clinical trial expenditure in 2023: $62.4 million
- Number of ongoing Phase I-III trials: 5
- Estimated trial participant enrollment: 412 patients
Researching and Developing Monoclonal Antibody Treatments
Monoclonal antibody research budget: $43.2 million in 2023.
| Antibody Type | Target Indication | Development Status |
|---|---|---|
| COVI-GUARD | COVID-19 Treatment | Phase II Trials |
| COVI-TRACK | COVID-19 Diagnostic | Completed Development |
Pursuing COVID-19 Therapeutic and Diagnostic Solutions
COVID-19 related program investment: $31.6 million in 2023.
- Number of COVID-19 therapeutic candidates: 3
- Number of diagnostic solutions: 2
- Cumulative COVID-19 program patents: 12
Advancing Regenerative Medicine Technologies
Regenerative medicine R&D allocation: $22.9 million in 2023.
| Technology Platform | Research Focus | Current Stage |
|---|---|---|
| STAR-SHOT | Stem Cell Therapy | Preclinical Development |
| RTX Platform | Regenerative Technologies | Early Research Phase |
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Key Resources
Extensive Patent Portfolio in Immunotherapy
As of Q4 2023, Sorrento Therapeutics holds 87 active patents specifically related to immunotherapy technologies. Patent breakdown:
| Patent Category | Number of Patents |
|---|---|
| Cancer Immunotherapy | 42 |
| Antibody Technologies | 29 |
| Therapeutic Platforms | 16 |
Advanced Research and Development Facilities
Sorrento maintains 3 primary research facilities:
- San Diego, California (Headquarters)
- Houston, Texas
- Shanghai, China
Skilled Scientific and Medical Research Teams
Research team composition as of 2024:
| Team Category | Total Personnel |
|---|---|
| PhD Researchers | 87 |
| Medical Doctors | 23 |
| Research Assistants | 112 |
Proprietary Antibody Screening Platforms
Sorrento has developed 4 proprietary antibody screening technologies:
- TRIDENT™ platform
- G-MAB™ library
- BEACON™ screening system
- STORM™ antibody discovery platform
Intellectual Property in Cancer Treatment Technologies
Intellectual property portfolio valuation as of 2024:
| IP Category | Estimated Value |
|---|---|
| Cancer Treatment Patents | $127.5 million |
| Antibody Technology IP | $93.2 million |
| Research Platform IP | $64.7 million |
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Value Propositions
Cutting-edge Cancer Immunotherapy Solutions
Sorrento Therapeutics focuses on developing innovative cancer immunotherapies with the following key characteristics:
| Therapy Type | Development Stage | Targeted Cancer Types |
|---|---|---|
| CAR-T Cell Therapies | Clinical Trials Phase | Solid Tumors, Hematological Cancers |
| Antibody-Drug Conjugates | Preclinical/Early Clinical | Multiple Cancer Indications |
Potential Breakthrough Treatments for Challenging Diseases
Sorrento's pipeline includes potential breakthrough treatments with the following characteristics:
- COVID-19 therapeutic antibody COVI-MSC
- ADPKD treatment STI-7984
- Pain management therapeutics
Personalized Therapeutic Approaches
The company's personalized medicine strategy involves:
| Technology | Precision Targeting | Patient Segment |
|---|---|---|
| Single-cell RNA Sequencing | Molecular Level Targeting | Oncology Patients |
| Chimeric Antigen Receptor Technologies | Immune Cell Modification | Cancer Immunotherapy |
Innovative Diagnostic and Treatment Technologies
Key technological innovations include:
- TRIDENT™ CAR-T platform
- G-MAB® antibody library
- SmartT™ cell therapy technologies
Targeted Molecular Medicine Strategies
Molecular targeting approach involves:
| Molecular Target | Technology Platform | Potential Application |
|---|---|---|
| HER2 Receptors | Antibody-Drug Conjugates | Breast Cancer Treatment |
| Immune Checkpoint Proteins | Monoclonal Antibodies | Immuno-Oncology |
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Customer Relationships
Direct Engagement with Medical Research Institutions
As of Q4 2023, Sorrento Therapeutics maintained research collaborations with 7 academic research institutions, focusing on immuno-oncology and COVID-19 therapeutic development.
| Institution Type | Number of Active Collaborations | Research Focus Areas |
|---|---|---|
| Academic Research Centers | 7 | Immuno-oncology, COVID-19 therapeutics |
Collaborative Partnerships with Pharmaceutical Companies
In 2023, Sorrento established strategic partnerships with 3 pharmaceutical companies for advanced therapeutic development.
- Collaboration with GenScript Biotech for antibody development
- Partnership with NantWorks for cancer immunotherapy research
- Joint research agreement with unnamed pharmaceutical partner
Scientific Conference and Industry Event Participation
Sorrento participated in 12 scientific conferences in 2023, presenting research findings and engaging with potential collaborators.
| Conference Type | Number of Conferences | Presentation Focus |
|---|---|---|
| Oncology Conferences | 5 | Cancer immunotherapy research |
| Infectious Disease Conferences | 4 | COVID-19 therapeutic developments |
| Biotechnology Symposiums | 3 | Innovative therapeutic platforms |
Transparent Communication of Research Progress
Sorrento issued 18 press releases in 2023, providing updates on clinical trials and research milestones.
- Quarterly financial and research updates
- Detailed clinical trial progress reports
- Investor and analyst communication platforms
Patient-Focused Therapeutic Development Approach
As of 2023, Sorrento had 5 ongoing clinical trials targeting patient-specific therapeutic interventions.
| Therapeutic Area | Number of Clinical Trials | Patient Population Target |
|---|---|---|
| Immuno-oncology | 3 | Cancer patients |
| Infectious Diseases | 2 | COVID-19 patients |
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Channels
Direct Sales to Pharmaceutical Partners
As of Q4 2023, Sorrento Therapeutics engaged in direct sales partnerships with the following pharmaceutical companies:
| Partner Company | Collaboration Focus | Estimated Value |
|---|---|---|
| Yuhan Corporation | COVID-19 Antibody Development | $25.3 million |
| GenExine | Vaccine Technology | $18.7 million |
Medical Conference Presentations
Sorrento Therapeutics participated in 12 major medical conferences in 2023, including:
- American Association for Cancer Research (AACR) Annual Meeting
- American Society of Clinical Oncology (ASCO) Annual Meeting
- Immuno-Oncology Summit
Scientific Publication Platforms
Publication metrics for 2023:
| Platform | Number of Publications | Total Citations |
|---|---|---|
| PubMed | 17 | 342 |
| Nature Journals | 3 | 156 |
Digital Communication and Investor Relations
Digital engagement statistics for 2023:
- Website visitors: 127,543
- Investor webinar attendees: 2,341
- Social media followers:
- LinkedIn: 18,234
- Twitter: 12,567
Regulatory Submission Channels
Regulatory submission data for 2023:
| Regulatory Agency | Number of Submissions | Therapeutic Areas |
|---|---|---|
| FDA | 5 | Oncology, COVID-19 |
| EMA | 2 | Cancer Immunotherapy |
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Customer Segments
Oncology Research Institutions
As of 2024, Sorrento Therapeutics targets oncology research institutions with specific market parameters:
| Research Institution Type | Potential Market Size | Research Focus |
|---|---|---|
| Academic Cancer Centers | 87 active centers | Immunotherapy research |
| National Cancer Institute Partners | 23 collaborative networks | Clinical trial development |
Pharmaceutical Companies
Pharmaceutical customer segment characteristics:
- Total potential pharmaceutical partnership targets: 42 companies
- Potential collaboration value: $127.6 million in potential licensing agreements
- Therapeutic areas of interest: Oncology, immunotherapy, rare diseases
Healthcare Providers
Healthcare provider segment analysis:
| Provider Category | Number of Potential Customers | Target Treatment Areas |
|---|---|---|
| Oncology Treatment Centers | 612 centers nationwide | Cancer immunotherapies |
| Specialized Treatment Clinics | 287 specialized facilities | Rare disease treatments |
Biotechnology Research Centers
Biotechnology research center market breakdown:
- Total addressable research centers: 214
- Potential collaborative research budget: $53.4 million
- Primary research domains: Immunooncology, cell therapies
Individual Patients with Complex Medical Conditions
Patient segment analysis:
| Disease Category | Potential Patient Population | Treatment Approach |
|---|---|---|
| Refractory Cancer Patients | 48,000 potential patients | Targeted immunotherapies |
| Rare Disease Patients | 12,500 potential patients | Specialized therapeutic interventions |
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Cost Structure
Extensive Research and Development Expenses
For the fiscal year 2022, Sorrento Therapeutics reported R&D expenses of $140.4 million. The company's research and development costs have been consistently high due to multiple ongoing therapeutic programs.
| Year | R&D Expenses | Percentage of Total Expenses |
|---|---|---|
| 2022 | $140.4 million | 68.3% |
| 2021 | $129.7 million | 65.9% |
Clinical Trial Funding
Sorrento Therapeutics invested $87.2 million specifically in clinical trial activities during 2022, covering multiple therapeutic areas including oncology, COVID-19 treatments, and pain management.
Patent Maintenance and Intellectual Property Costs
The company spent approximately $12.5 million on patent maintenance and intellectual property protection in 2022.
- Number of active patents: 284
- Patent filing and maintenance cost per patent: Average $44,000
- Total intellectual property portfolio investment: $15.3 million
Personnel and Scientific Talent Acquisition
Personnel expenses for scientific and research staff totaled $52.6 million in 2022.
| Employee Category | Number of Employees | Average Annual Compensation |
|---|---|---|
| Research Scientists | 187 | $215,000 |
| Clinical Researchers | 124 | $185,000 |
Laboratory and Technology Infrastructure Investments
In 2022, Sorrento invested $34.8 million in laboratory equipment, technology infrastructure, and research facilities.
- Laboratory equipment upgrade: $22.3 million
- Technology infrastructure: $8.5 million
- Research facility maintenance: $4 million
Sorrento Therapeutics, Inc. (SRNE) - Business Model: Revenue Streams
Potential Milestone Payments from Partnerships
As of Q4 2023, Sorrento Therapeutics reported potential milestone payments from strategic partnerships, including:
| Partner | Potential Milestone Payment | Associated Program |
|---|---|---|
| Yuhan Corporation | Up to $360 million | COVID-19 therapeutic development |
| Celularity Inc. | Up to $250 million | Cell therapy collaborations |
Licensing Intellectual Property
Sorrento's IP licensing revenue streams include:
- Antibody technology platforms
- Cancer immunotherapy patents
- COVID-19 related therapeutic technologies
Future Pharmaceutical Product Sales
Projected pharmaceutical product revenue potential:
| Product | Estimated Market Potential | Development Stage |
|---|---|---|
| COVI-MSC | $150-200 million | Clinical trials |
| TRPV1 Antagonist | $100-150 million | Preclinical development |
Research Grants and Government Funding
Government and research funding sources:
- Department of Defense grants: $5.7 million
- National Institutes of Health research support: $3.2 million
- COVID-19 related research funding: $12.4 million
Potential Therapeutic Product Commercialization
Projected commercialization revenue streams:
| Therapeutic Area | Estimated Annual Revenue Potential | Market Segment |
|---|---|---|
| Immunotherapy | $250-300 million | Oncology |
| Pain Management | $100-150 million | Neurological therapeutics |
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.